huPBMC-T Mice

Alfa Cytology's huPBMC-T mice is an innovative platform specifically designed to accelerate T-cell immunotherapy development. By reconstituting a functional human T-cell immune system, this model provides drug developers with a highly reliable preclinical evaluation tool. Whether for CAR-T cell therapy, immune checkpoint inhibitors, or bispecific antibodies, the huPBMC-T model can provide highly clinically predictive efficacy data in a short period. We not only provide high-quality animal models but also offer end-to-end professional services from experimental design and model establishment to data analysis.

Introduction tohuPBMC-T Mice

The huPBMC-T model establishes a robust humanized immune system by engrafting healthy donor-derived PBMCs into immunodeficient NCG or NSG mice, leading to a predominant reconstruction of functional human T cells.

• The optimized protocol enables experiments to commence within a remarkably short timeframe of 10-14 days.
• Hu-Immune™ platform achieves a consistent model success rate exceeding 90%. A rigorous QC system ensures high data reliability by maintaining the hCD45+ cell coefficient of variation below 50%.
• The model provides a stable experimental window of over 3 weeks, which is critical for obtaining meaningful pharmacodynamic data and has been demonstrated to support effective T cell infiltration into tumor tissues.

Advantages of huPBMC-T Mice

Applications of huPBMC-T Mice

Cellular Immunotherapy Evaluation

Safety and efficacy evaluation of cellular therapies including CAR-T, TCR-T, and TIL.

Immune Checkpoint Inhibitor Research

Monotherapy or combination therapy research on checkpoint inhibitors including PD-1/PD-L1, CTLA-4, and 4-1BB.

Tumor Microenvironment Modulation Strategies

Drug development and mechanism research on tumor microenvironment targets including TGF-β and Treg.

Case Study

Case 1: Evaluation of Treg-Modulating and Cytokine Therapies in huPBMC-T Humanized Model

Overview

Assess antitumor activity and immune reconstitution in huPBMC-T humanized NCG model using a Treg-modulating anti-CD25 antibody and a cytokine regimen.

Study Information

• Humanized Model: huPBMC-T on NCG strain
• Tumor Model: KAPPAS299 human lymphoma cell line
• Treatment: Novel Treg-targeting immunomodulator

Results

• Effective Treg Modulation: The test drug effectively modulated the intratumoral Treg population, reducing this key immunosuppressive cell type within the tumor microenvironment.
• Promoted Anti-tumor Activity: Modulation of Tregs was associated with promoted anti-tumor activity and tumor growth inhibition.
• Model Validation: The study validated the huPBMC-T model's capability to support the evaluation of therapies targeting specific immune cell populations within a complex humanized TIME.

Fig. 3 Anti-tumor efficacy and human immune reconstitution in huPBMC-T humanized NCG model.

Case 2: PD-1 Inhibitor and TGF-β Target Study in huPBMC-T Humanized Model

Overview

This study aimed to assess the efficacy of a PD-1 inhibitor, both as monotherapy and in combination with a TGF-β signaling inhibitor, showcasing the model's power in evaluating combination immunotherapy strategies.

Study Information

• Humanized Model: huPBMC-T on NCG strain
• Tumor Model: Jeko-1 human mantle cell lymphoma
• Treatment: PD-1 inhibitor, TGF-β signaling inhibitor, and their combination

Results

• Clinical-like Response: The model successfully recapitulated a clinical-like response to PD-1 blockade, confirming its relevance for checkpoint inhibitor evaluation.
• Synergistic Effect: The combination of PD-1 and TGF-β inhibition clearly revealed a synergistic effect, leading to enhanced tumor growth suppression compared to either agent alone.
• Platform for Combination Therapy: The results highlight the model's power in deconvoluting complex interactions between immunotherapeutic agents and supporting the development of combination strategies.

Fig. 4 Anti-tumor efficacy of PD-1, GARP-ab, and their combination in huPBMC-T humanized NCG model.

The huPBMC-T model is the ideal preclinical evaluation platform for your T-cell immunotherapy development. Alfa Cytology's Hu-Immune™ platform provides end-to-end professional services from model establishment to data analysis. Contact our scientific team now for customized solutions.

For research use only.